Q1 FY27 saw record revenue of INR 7,119 crore, with strong growth in India and North America, and robust launches in chronic and respiratory therapies. EBITDA margin was 16.7%, with guidance maintained at 18.5%-20% for FY27, contingent on new product launches. North America targets a $1 billion EBIT run rate by year-end.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.